



NEALS Announcement

The Northeast ALS Consortium in collaboration with Isis Pharmaceuticals, Inc. launches a phase I safety study using ISIS-SOD1_{Rx} for the treatment of persons with familial ALS with the SOD1 mutation

NEALS is pleased to announce enrollment of the first subject in this phase 1 study of ISIS-SOD1_{Rx} for patients with familial ALS with the SOD1 gene mutation, sponsored by Isis Pharmaceuticals, Inc, Carlsbad, CA. Additional support is provided by the ALS Association and the Muscular Dystrophy Association. This study will examine the safety, tolerability, and pharmacokinetics (the actions of the drug in the body) of ISIS-SOD1_{Rx} in up to 32 participants with SOD1 familial ALS.

The six participating NEALS sites include: Washington University (St. Louis, MO), Massachusetts General Hospital (Boston, MA), Center for Neurological Study (La Jolla, CA), Johns Hopkins University (Baltimore, MD), Methodist Neurological Institute (Houston, TX), and Carolinas Medical Center (Charlotte, NC). Study Chairs are Drs. Timothy Miller at Washington University in St. Louis and Merit Cudkowicz at Massachusetts General Hospital.

For more information on the study, please contact the Coordination Center:

Pat Andres: phone: 617-724-8995; email: pandres1@partners.org

Patients may contact individual Study Coordinators at participating sites. Contact information for approved, active recruiting sites is found on the www.clinicaltrials.gov website:

<http://clinicaltrials.gov/ct2/show/NCT01041222?term=ALS&recr=Open&type=Intr&phase=0&rank=6>